FARMINGDALE, N.Y., Oct. 25, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, neurosurgery, wound debridement, skull based surgery, laparoscopic surgery and other surgical applications, has announced its plans to participate in the North American Spine Society (NASS) 2016 Annual Meeting to be held in Boston on October 26 - 29, 2016.
NASS is a global multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical, value and evidence-based spine care for patients. The NASS 2016 Annual Meeting represents the world's largest spine meeting and exhibition. Approximately 3,500 spine care professionals are expected to attend this year's meeting.
During exhibit hours there will be scheduled Meet The Experts sessions at the Misonix booth. Guest surgeons will include Dr. Nicholas Renaldo, Medical Director of Spine Surgery at Vassar Brothers Medical Center, Poughkeepsie NY; Dr. Eric Woodard, Chief of the Section of Neurosurgery, New England Baptist Hospital, Boston MA; and Dr. Connor Telles from Sierra Pacific Orthopedics in Fresno, CA. NASS attendees will be able to engage these surgeon BoneScalpel users at the Misonix booth to learn first-hand about their positive experiences with BoneScalpel use in adolescent and adult spine surgery.
Misonix will also be hosting a BoneScalpel hands-on cadaveric workshop on October 26. The workshop entitled, Ultrasonic BoneScalpel Techniques in Complex Spine will be facilitated by Isador Lieberman, MD, Director of the Scoliosis and Spine Tumor Center at the Texas Back Institute in Plano, TX. Dr. Lieberman will demonstrate and speak to his clinical usage of the BoneScalpel and surgeon attendees will have the opportunity for hands-on experience with the BoneScalpel system. It is anticipated that there will be more than 35 spine surgeons trained on the use of BoneScalpel.
Scott Ludecker, senior vice president of global sales and marketing for Misonix, said, "The BoneScalpel Hands-On Workshops that we are hosting at NASS this year will allow participants to not only trial the BoneScalpel on cadaveric specimens, but benefit from the instruction and actual experience of key opinion leading surgeons who have adopted the BoneScalpel into their clinical practices. Learning how to use BoneScalpel in a formal lab setting such as this workshop is an important step for surgeons to gain confidence with the device and to see for themselves why so many of their colleagues around the world have made BoneScalpel an important part of their surgical armamentarium. We look forward to a great event this year."
"BoneScalpel is increasingly becoming adopted by the spinal surgeon community for the purpose of making precise and safe bone cuts during challenging spine surgeries," said Stavros Vizirgianakis, Interim Misonix CEO. "Misonix is very pleased to participate in NASS this year as we value the opportunity to engage some of the most prominent spine surgeons in the world. We are looking forward to providing platforms for the attendees to be able to trial first-hand the technologically advanced BoneScalpel system. Our commitment to medical education and for training surgeons on advanced surgical techniques with our advanced technology remains central to our mission at Misonix."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
For more information:
Last updated on: 26/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.